Treatment of patients with MRSA bacteria in their throat by irrigation with the drug mupirocin

Treatment of MRSA throat carriage with mupirocin irrigation - Throat-MRSA-Irrig

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2014-005308-12-DK

Enrollment

Registered

2018-08-14

Start date

2018-09-07

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patientents being MRSA positive for a minimum of 6 months and concluded at least one konventional topical treatments unsuccessfully MedDRA version: 20.0 Level: PT Classification code 10061554 Term: Staphylococcal pharyngitis System Organ Class: 10021881 - Infections and infestations

Interventions

Trade Name: Bactroban Product Name: BACTROBAN Product Code: ACT D06AX09 Pharmaceutical Form: Ointment INN or Proposed INN: MUPIROCIN CALCIUM CAS Number: 8000026-92-8 Other descriptive name: MUPIROCI

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: MRSA positive for a minimum of 6 months Completed at least one conventional topical treatments without success. 18 years of age or above and able to consent The S.aureus isolat is mupirocin sensitive Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 10 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 10

Exclusion criteria

Exclusion criteria: Sufforing from acute or chronic ilness in the ear, nose or throat Sensitive to mupirocin Risk of re-infection from environment (work, living conditions - eg work or living at a pig farm) Negative

Design outcomes

Primary

Measure	Time frame
Main Objective: Aim • To investigate whether nasopharyngeal carriers of MRSA are decolonised for MRSA by combining the konventional topical MRSA reatment with rhinopharynx irrigation with mupirocin ;Secondary Objective: To investigate if the treatment regimen can be used as first line tratment in newly diagnosed patients carrying MRSA in their throat ;Primary end point(s): Free of MRSA after 1 month (plus/minus 1 week), and free of MRSA after a minimum of 6 months;Timepoint(s) of evaluation of this end point: 1 month and 6 months	—

Measure

Time frame

Main Objective: Aim • To investigate whether nasopharyngeal carriers of MRSA are decolonised for MRSA by combining the konventional topical MRSA reatment with rhinopharynx irrigation with mupirocin ;Secondary Objective: To investigate if the treatment regimen can be used as first line tratment in newly diagnosed patients carrying MRSA in their throat ;Primary end point(s): Free of MRSA after 1 month (plus/minus 1 week), and free of MRSA after a minimum of 6 months;Timepoint(s) of evaluation of this end point: 1 month and 6 months

—

Secondary

Measure	Time frame
Secondary end point(s): Same;Timepoint(s) of evaluation of this end point: 1 month and 6 months	—

Countries

Denmark

Contacts

Public ContactHead of Research and Innovation

Region Sjælland, Operations, Research and Innovation

jesgr@regionsjaelland.dk4593567728

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026